Patents by Inventor Anna Leitgeb

Anna Leitgeb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Low anticoagulant heparins
    Patent number: 9480701
    Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tiddia, Lino Liverani
  • Use of chemically modified heparin derivates in sickle cell disease
    Patent number: 9480702
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • LOW ANTICOAGULANT HEPARINS
    Publication number: 20150031638
    Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 29, 2015
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tidia, Lino Liverani
  • USE OF CHEMICALLY MODIFIED HEPARIN DERIVATES IN SICKLE CELL DISEASE
    Publication number: 20140364369
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas